Brain Sciences, Vol. 7, Pages 137: Immunotherapy for Pediatric Brain Tumors

Brain Sciences, Vol. 7, Pages 137: Immunotherapy for Pediatric Brain Tumors

Brain Sciences doi: 10.3390/brainsci7100137

Authors: Elias Sayour Duane Mitchell

Malignant brain tumors are the most common cause of solid cancer death in children. New targeted therapies are vital to improve treatment outcomes, but must be developed to enable trafficking across the blood brain barrier (BBB). Since activated T cells cross the BBB, cancer immunotherapy can be harnessed to unlock the cytotoxic potential of the immune system. However, standard of care treatments (i.e., chemotherapy and radiation) applied concomitant to pediatric brain tumor immunotherapy may abrogate induction of immunotherapeutic responses. This review will discuss the development of immunotherapies within this paradigm using emerging approaches being investigated in phase I/II trials in children with refractory brain tumors, including checkpoint inhibitors, vaccine immunotherapy, and adoptive cell therapy.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iql0CW
via IFTTT